



تجمع الرياض الصحي الثاني Riyadh Second Health Cluster



Neuropathy Secondary to Drugs (II)

Cancer-related neuropathy is a common longterm health effect impacting one-third of cancer survivors. It can result from:

- Tumors compressing on and/or infiltrating the peripheral nerves
- Certain cancer therapies such as surgery, chemotherapy and/or radiation therapy.



It is a debilitating side effect of cancer treatment that may occur when chemotherapeutic agents damage the peripheral nerves that are outside the brain and spinal cord.

Chemotherapy agents which may cause CIPN

- Cisplatin, carboplatin, and oxaliplatin
- Paclitaxel, docetaxel, and cabazitaxel
- Ixabepilone
- Vinblastine, vincristine, vinorelbine, and etoposide
- Thalidomide, lenalidomide, and pomalidomide
- Bortezomib and carfilzomib
- Eribulin

CIPN symptoms begin in the extremities – the

hands and feet – and then move upwards.



Symptoms

CIPN affects activities of daily living and quality of life

Pain	Burning	Tingling
Numbness	Electric shock	Pins and needles
	Temperature sensitivity	



What can I do?

Recognize the symptoms early

- Assess the neuropathy symptoms as soon as possible
- Confirm if the neuropathy is related to the cancer therapy, the cancer itself, or a preexisting neuropathy
- Determine if the cancer therapy regimen should be modified to minimize neuropathy's debilitating effects.
- > Incorporate pain relief and rehabilitative care
- Protect your hands and feet
 - Wear supportive footwear that also protects from injury
 - Check temperature of water before you shower or wash your hands

• Inspect hands and feet daily for any cuts, abrasions, burns, and injury

Prevent falls and fall-related injuries

Use handrails, canes, and other assistive devices as needed to help address balance issues, improve mobility and function, and preserve independence

Risk factors

- Age
- Co-morbid health conditions
- Pre-existing neuropathy
- Longer duration of cancer therapy
- High cumulative dose
- Type of cancer therapeutic agent

One third of them will develop

cancer-related neuropathies

New medicines in development

- EMA401 (Spinifex)
- KRN5500 (DARA BioSciences)
- Tetrodotoxin (Wex Pharmaceuticals)
- Duloxetine (Eli Lilly)



HEM3.16.000146

